p.7 抽出テキスト

June 18/25, 2019 Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625 e1088

CLINICAL STATEMENTS AND GUIDELINES

Health Initiative, a contemporary multiethnic cohort of postmenopausal women, appeared to indicate that these pooled cohort equations overestimated ASCVD risk. However, when event surveillance was improved by data from Centers for Medicare & Medicaid Services, the authors found that the equations discriminated risk well.S2.1.3-4 Several other factors associate with ASCVD, and in the present document these are called risk-enhancing factors. Projections of future risk derived from major risk factors and risk-enhancing factors can be used to adjust the intensity of LDL-lowering therapy. 2.2 Measurements of LDL-C

and Non–HDL-C

Recommendations for Measurements of LDL-C and Non–HDL-C Referenced studies that support recommendations are summarized in Online Data Supplement 1.

COR LOE Recommendations

I B-NR 1.  In adults who are 20 years of age or older and not on lipid-lowering therapy, measurement of either a fasting or a nonfasting plasma lipid profile is effective in estimating ASCVD risk and documenting baseline LDL-C.S2.2-1–S2.2-6

Table 2.  Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

Downloaded from http://ahajournals.org by on October 7, 2026